Spero Therapeutics (SPRO) Earnings Analysis

Spero Therapeutics (SPRO) next reports earnings on 2026-08-11, consensus EPS -0.17 USD. Last quarter (2026-03-26) it beat with EPS 0.53 USD vs -0.2 USD est (+365%). It has beaten estimates in 3/4 recent quarters (75%). Trailing P/E 4.71.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does SPRO next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.17 USD
Revenue estimate0.00B

SPRO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-260.53 USD-0.2 USD+365%Beat
2025-11-13-0.13 USD-0.25 USD+48%Beat
2024-11-14-0.32 USD-0.27 USD-18.5%Miss
2024-08-05-0.33 USD-0.35 USD+5.7%Beat

Beat rate: 3/4 (75%) over reported quarters with consensus data.

SPRO valuation and analyst view

Trailing P/E4.71
Trailing EPS0.26597 USD
Price / book1.37
Dividend yield0.00%
Market cap0.08B
Analyst consensusBuy (6 buy / 5 hold / 2 sell)

Related research pages

Frequently asked questions

When is Spero Therapeutics (SPRO)'s next earnings date?

Spero Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.17 USD and revenue estimate of 0.00B.

Did SPRO beat earnings last quarter?

In its 2026-03-26 report, SPRO posted EPS of 0.53 USD versus a -0.2 USD estimate — a beat of 365%.

What is SPRO's earnings track record?

Over the last 4 reported quarters with consensus data, SPRO beat estimates 3 times (75%).

What is SPRO's current P/E ratio and EPS?

SPRO trades at a trailing P/E of 4.71 on trailing EPS of 0.2659668720672286 USD.

What do analysts rate SPRO?

Analyst consensus is "Buy" across 13 ratings (0 strong buy, 6 buy, 5 hold, 2 sell, 0 strong sell).